/

Empresas

Ve

No verificado

Verastem Oncology

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

80 Comunicados de prensa

Ver todos los comunicados de prensa

06/08/2026

Mercado laboral

Mercado de valores

Web y redes sociales

Telefonía

Industria

Oncología

Salud

Medicina - Varios

Sanidad

Farmacéutica

Biotecnología

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Fuente

Verastem Oncology

Editor

1.00

0

28/07/2026

Industria

Oncología

Salud

Medicina - Varios

Sanidad

Farmacéutica

Biotecnología

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

Fuente

Verastem Oncology

Editor

1.00

0

23/07/2026

Web y redes sociales

Telefonía

Finanzas

Mercado de valores

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026

Fuente

Verastem Oncology

Editor

1.00

0

22/07/2026

Industria

Ciencia

Biotecnología

Farmacéutica

Oncología

Sanidad

Salud

Medicina - Varios

Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

Fuente

Verastem Oncology

Editor

1.00

0

02/07/2026

Oncología

Salud

Medicina - Varios

Sanidad

Farmacéutica

Biotecnología

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fuente

Verastem Oncology

Editor

1.00

0

23/06/2026

Web y redes sociales

Industria

Ciencia

Biotecnología

Farmacéutica

Oncología

Sanidad

Salud

Medicina - Varios

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

Fuente

Verastem Oncology

Editor

1.00

0

17/06/2026

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

Fuente

Verastem Oncology

Editor

1.00

0

16/06/2026

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer

Fuente

Verastem Oncology

Editor

1.00

0

15/06/2026

Web y redes sociales

Telefonía

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program

Fuente

Verastem Oncology

Editor

1.00

0

03/06/2026

Industria

Oncología

Higiene alimentaria

Salud

Medicina - Varios

Farmacéutica

Biotecnología

Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Fuente

Verastem Oncology

Editor

1.00

0

Seguidores

0

Compatibilidad

0